Literature DB >> 12204056

Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma.

Akio Sakamoto1, Yoshinao Oda, Toshisada Adachi, Tsuyoshi Saito, Sadafumi Tamiya, Yukihide Iwamoto, Masazumi Tsuneyoshi.   

Abstract

CONTEXT: beta-Catenin is an adhesion molecule that also plays a role in the Wnt signaling pathway. Objective.-To analyze beta-catenin mutation and accumulation in a series of liposarcomas and malignant fibrous histiocytomas.
DESIGN: beta-Catenin mutation in exon 3 was studied using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing analysis in 30 formalin-fixed, paraffin-embedded liposarcomas. The tumors included 12 dedifferentiated liposarcomas, characterized by both high-grade anaplastic components and well-differentiated liposarcoma components, plus 18 well-differentiated liposarcomas (10 lipoma-like and 8 sclerosing-type cases). The 2 components of dedifferentiated liposarcomas were analyzed independently. beta-Catenin accumulation in the nuclei or cytoplasm and Ki-67 expression (cell-proliferation marker, MIB-1 labeling index) were examined immunohistochemically. Nine storiform-pleomorphic-type malignant fibrous histiocytomas were also studied.
RESULTS: Dedifferentiated liposarcomas showed mutation in 2 cases (17%) and accumulation in 5 cases (42%). One of the 2 cases that showed mutations had a mutation in the well-differentiated component; this mutation was silent. The other case had mutations that differed between the 2 components. In well-differentiated liposarcomas, mutation was not seen in any of the cases (0/18; 0%); however, accumulation was seen frequently in the sclerosing-type cases (5/8; 63%), but not in the lipoma-like cases (0/10; 0%). Malignant fibrous histiocytomas showed mutation and accumulation in 5 (56%) and 4 (44%) cases, respectively, without any exact correlation between the cases. Cases with accumulation had a higher MIB-1 labeling index than those without, among both the sclerosing-type well-differentiated liposarcomas (P <.05) and the malignant fibrous histiocytomas.
CONCLUSIONS: Our results suggest the possible involvement of beta-catenin activation caused by beta-catenin mutation in liposarcoma and malignant fibrous histiocytoma, but the contribution would seem to be different, depending on the tumor type. beta-Catenin accumulation is also thought to be related to cell proliferation in some of the cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204056     DOI: 10.5858/2002-126-1071-CAAGMI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

1.  Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases.

Authors:  William B Laskin; Jerzy P Lasota; John F Fetsch; Anna Felisiak-Golabek; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

2.  Myotonic dystrophy and lipoma: a new association.

Authors:  Yohsuke Yagi; Akira Machida; Shuta Toru; Takayoshi Kobayashi; Tomonari Amano; Katsuiku Hirokawa; Masanobu Kitagawa
Journal:  Neurol Sci       Date:  2011-12-21       Impact factor: 3.307

Review 3.  Liposarcoma: a soft tissue tumor with many presentations.

Authors:  H J Mankin; K P Mankin; D C Harmon
Journal:  Musculoskelet Surg       Date:  2014-07-22

Review 4.  The Wnt signaling pathway and its role in tumor development.

Authors:  B Lustig; J Behrens
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-18       Impact factor: 4.553

5.  MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Authors:  Pingyu Zhang; Katelynn Bill; Juehui Liu; Eric Young; Tingsheng Peng; Svetlana Bolshakov; Aviad Hoffman; Yechun Song; Elizabeth G Demicco; Dolores Lopez Terrada; Chad J Creighton; Matthew L Anderson; Alexander J Lazar; George G Calin; Raphael E Pollock; Dina Lev
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

6.  Breast carcinoma metastasis in recurrent myxoid liposarcoma.

Authors:  Fevziye Kabukcuoglu; Yavuz Kabukcuoglu; Canan Tanik; Damlanur Sakiz; Semra Karsidag
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

Authors:  Shingo Sato; Yuning J Tang; Qingxia Wei; Makoto Hirata; Angela Weng; Ilkyu Han; Atsushi Okawa; Shu Takeda; Heather Whetstone; Puvindran Nadesan; David G Kirsch; Jay S Wunder; Benjamin A Alman
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

8.  Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways.

Authors:  Ralf J Rieker; Juergen Weitz; Burkhard Lehner; Gerlinde Egerer; Andrea Mueller; Bernd Kasper; Peter Schirmacher; Stefan Joos; Gunhild Mechtersheimer
Journal:  Virchows Arch       Date:  2009-12-29       Impact factor: 4.064

9.  Role of β-catenin expression in paediatric mesenchymal lesions: a tissue microarray-based immunohistochemical study.

Authors:  A Santoro; G Pannone; M E Errico; D Bifano; G Lastilla; P Bufo; C Loreto; V Donofrio
Journal:  Eur J Histochem       Date:  2012-07-02       Impact factor: 3.188

10.  Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases.

Authors:  Pinelopi Gogou; Emilios Pakos; Anna Batistatou; Ioannis Panelos; Evangelos Briasoulis; Dimitrios Stefanou; Nikoforos Apostolikas; Periclis Tsekeris
Journal:  World J Surg Oncol       Date:  2012-02-02       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.